News

Federal lawmakers are asking the U.S. Food and Drug Administration (FDA) to provide additional data and documents related to the agency’s controversial decision to grant accelerated approval to Biogen‘s Aduhelm (aducanumab) as a treatment for Alzheimer’s disease. U.S. Rep. Frank Pallone, Jr., chair of the House Committee on…

The Adira Foundation is inviting people with neurodegenerative diseases and their caregivers to join a grant proposal review committee. A nonprofit foundation, its mission is to unite people affected by some of most common neurodegenerative diseases — namely, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and multiple sclerosis —…

Each September, people from around the globe come together to heighten awareness of Alzheimer’s disease and push back against stigmas around dementia. This year marks a decade of advocacy, as supporters observe the 10th World Alzheimer’s Month. Throughout the month, patients, caregivers, and advocates will share messages and stories…

Using a genetic approach that can “read” the entire human genetic signature, researchers have identified 13 gene variants — or mutations — associated with Alzheimer’s disease risk whose functions are related to neuronal or nerve cell development and connections. Moreover, the…

Every participant in the Phase 2/3 GAIN clinical trial, which is testing Cortexyme’s experimental medication COR388 (atuzaginstat) in people with Alzheimer’s disease, showed evidence of infection by Porphyromonas gingivalis (P. gingivalis), according to a new analysis. In particular, all patients analyzed at the beginning of the study who had…

A partnership agreement will allow INmune Bio to continue using biomarker imaging technology by Imeka in future clinical trials evaluating XPro1595, the company’s investigational therapy for Alzheimer’s disease. INmune Bio is planning to initiate a Phase 2 study of XPro1595 in Alzheimer’s patients this year, it stated in a…

I-Mab will launch a Phase 1 clinical trial evaluating Protollin, its nasal spray immunotherapy candidate for Alzheimer’s disease. The biotech company’s announcement follows the recent approval of an investigational new drug (IND) application for Protollin by the U.S. Food and Drug Administration (FDA). “Advancing Protollin into clinic is…

Phil Frengs is on a coast-to-coast mission to raise money and awareness for Alzheimer’s disease, always thinking of, and honoring, his wife Mimi, who was diagnosed with the condition in November 2013. Frengs, a racing aficionado, is the president and CEO of Legistics, which specializes in document support services…

Note: An update to this story on Aug. 23, 2021, changed the percentage of assisted living facilities that have incorporated personalized music into their care from 3% to 10%, according to corrected information from Dan Cohen.  According to Dan Cohen, founder of the organization Right to Music, about 25,000…

Altoida’s artificial intelligence (AI)-powered device, intended to indicate the start of Alzheimer’s disease in adults with mild dementia but no evident disease symptoms, has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). The non-invasive device uses a software that measures and monitors neurocognitive function to…